@article{PAR00010187,
  title = {{HIV}-1 genetic diversity and drug resistance among {S}enegalese patients in the public health system},
  author = {{T}hiam, {M}. and {D}iop-{N}diaye, {H}. and {D}iouf, {A}. {D}. and {V}idal, {N}icole and {N}diaye, {O}. and {N}diaye, {I}. and {N}gom-{G}ueye, {N}. {F}. and {D}iallo, {S}. and {D}iongue, {O}. {D}. and {C}amara, {M}. and {S}eck, {A}. and {M}boup, {S}. and {T}oure-{K}ane, {C}.},
  editor = {},
  language = {{ENG}},
  abstract = {{I}n this study, we investigated the prevalence of human immunodeficiency virus type 1 ({HIV}-1) drug resistance mutations and genetic variability among {S}enegalese patients undergoing highly active antiretroviral therapy ({ART}) in the public health system. {W}e conducted a cross-sectional study of 72 patients with suspected therapeutic failure. {HIV}-1 genotyping was performed with {V}iroseq {HIV}-1 {G}enotyping {S}ystem v2.0 or the procedure developed by the {ANRS} {AC}11 resistance study group, and a phylogenetic analysis was performed. {T}he median follow-up visit was at 40 (range, 12 to 123) months, and the median viral load was 4.67 (range, 3.13 to 6.94) log(10) copies/ml. {T}he first-line therapeutic regimen was nucleoside reverse transcriptase inhibitors ({NRTI}s) plus efavirenz ({EFV}) or {NRTI}s plus nevirapine ({NVP}) (54/72 patients; 75%), and the second-line therapy was {NRTI}s plus a protease inhibitor ({PI}/r) (18/72; 25%). {F}ifty-five patients (55/72; 76.39%) had at least one drug resistance mutation. {T}he drug resistance rates were 72.22 and 88.89% for the first-line and second-line {ART}s, respectively. {I}n {NRTI} mutations, thymidine analog mutations ({TAM}s) were found in 50.79% and the {M}184{V} mutation was found in 34.92% of the samples. {F}or non-{NRTI} resistance, we noted a predominance of the {K}103{N} mutation (46.27%). {F}or {PI}/r, several cases of mutations were found with a predominance of {M}46{I} and {L}76{V}/{F} at 24% each. {T}he phylogenetic analysis revealed {CRF}02_{AG} as the predominant circulating recombinant form (43/72; 59.72%). {W}e found a high prevalence of resistance mutations and a high rate of {TAM}s among {S}enegalese patients in the public health system. {T}hese findings emphasize the need to improve virological monitoring in resource-limited settings.},
  keywords = {{SENEGAL}},
  booktitle = {},
  journal = {{J}ournal of {C}linical {M}icrobiology},
  volume = {51},
  numero = {2},
  pages = {578--584},
  ISSN = {0095-1137},
  year = {2013},
  DOI = {10.1128/jcm.02452-12},
  URL = {https://www.documentation.ird.fr/hor/{PAR}00010187},
}